1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN
Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [CrossRef]
[PubMed]
Morgan, E.; Soerjomataram, I.; Rumgay, H.; Coleman, H.G.; Thrift, A.P.; Vignat, J.; Laversanne, M.; Ferlay, J.; Arnold, M. The
Global Landscape of Esophageal Squamous Cell Carcinoma and Esophageal Adenocarcinoma Incidence and Mortality in 2020
and Projections to 2040: New Estimates From GLOBOCAN 2020. Gastroenterology 2022, 163, 649–658.e2. [CrossRef] [PubMed]
Smyth, E.C.; Lagergren, J.; Fitzgerald, R.C.; Lordick, F.; Shah, M.A.; Lagergren, P.; Cunningham, D. Oesophageal Cancer. Nat. Rev.
Dis. Primers 2017, 3, 1–21. [CrossRef]
Kitagawa, Y.; Uno, T.; Oyama, T.; Kato, K.; Kato, H.; Kawakubo, H.; Kawamura, O.; Kusano, M.; Kuwano, H.; Takeuchi, H.; et al.
Esophageal Cancer Practice Guidelines 2017 Edited by the Japan Esophageal Society: Part 1. Esophagus 2019, 16, 1–24. [CrossRef]
Kitagawa, Y.; Uno, T.; Oyama, T.; Kato, K.; Kato, H.; Kawakubo, H.; Kawamura, O.; Kusano, M.; Kuwano, H.; Takeuchi, H.; et al.
Esophageal Cancer Practice Guidelines 2017 Edited by the Japan Esophageal Society: Part 2. Esophagus 2019, 16, 25–43. [CrossRef]
Kato, K.; Cho, B.C.; Takahashi, M.; Okada, M.; Lin, C.Y.; Chin, K.; Kadowaki, S.; Ahn, M.J.; Hamamoto, Y.; Doki, Y.; et al.
Nivolumab versus Chemotherapy in Patients with Advanced Oesophageal Squamous Cell Carcinoma Refractory or Intolerant
to Previous Chemotherapy (ATTRACTION-3): A Multicentre, Randomised, Open-Label, Phase 3 Trial. Lancet Oncol. 2019, 20,
1506–1517. [CrossRef]
Janjigian, Y.Y.; Shitara, K.; Moehler, M.; Garrido, M.; Salman, P.; Shen, L.; Wyrwicz, L.; Yamaguchi, K.; Skoczylas, T.; Campos
Bragagnoli, A.; et al. First-Line Nivolumab plus Chemotherapy versus Chemotherapy Alone for Advanced Gastric, GastroOesophageal Junction, and Oesophageal Adenocarcinoma (CheckMate 649): A Randomised, Open-Label, Phase 3 Trial. Lancet
2021, 398, 27–40. [CrossRef]
Özgüroglu,
M.; Kilickap, S.; Sezer, A.; Gümü¸s, M.; Bondarenko, I.; Gogishvili, M.; Nechaeva, M.; Schenker, M.; Cicin, I.; Ho,
G.F.; et al. First-Line Cemiplimab Monotherapy and Continued Cemiplimab beyond Progression plus Chemotherapy for
Advanced Non-Small-Cell Lung Cancer with PD-L1 50% or More (EMPOWER-Lung 1): 35-Month Follow-up from a Mutlicentre,
Open-Label, Randomised, Phase 3 Trial. Lancet Oncol. 2023, 24, 989–1001. [CrossRef]
Colombo, N.; Dubot, C.; Lorusso, D.; Caceres, M.V.; Hasegawa, K.; Shapira-Frommer, R.; Tewari, K.S.; Salman, P.; Hoyos Usta, E.;
Yañez, E.; et al. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. N. Engl. J. Med. 2021, 385, 1856–1867.
[CrossRef] [PubMed]
Bagchi, S.; Yuan, R.; Engleman, E.G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms
of Response and Resistance. Annu. Rev. Pathol. Mech. Dis. 2021, 16, 223–249. [CrossRef]
Komohara, Y.; Kurotaki, D.; Tsukamoto, H.; Miyasato, Y.; Yano, H.; Pan, C.; Yamamoto, Y.; Fujiwara, Y. Involvement of Protumor
Macrophages in Breast Cancer Progression and Characterization of Macrophage Phenotypes. Cancer Sci. 2023, 114, 2220–2229.
[PubMed]
Baba, Y.; Nomoto, D.; Okadome, K.; Ishimoto, T.; Iwatsuki, M.; Miyamoto, Y.; Yoshida, N.; Baba, H. Tumor Immune Microenvironment and Immune Checkpoint Inhibitors in Esophageal Squamous Cell Carcinoma. Cancer Sci. 2020, 111, 3132–3141.
[PubMed]
Sumitomo, R.; Huang, C.L.; Fujita, M.; Cho, H.; Date, H. Differential Expression of PD-L1 and PD-L2 Is Associated with the
Tumor Microenvironment of TILs and M2 TAMs and Tumor Differentiation in Non-Small Cell Lung Cancer. Oncol. Rep. 2022, 47,
1–11. [CrossRef]
Xiao, Y.; Yu, D. Tumor Microenvironment as a Therapeutic Target in Cancer. Pharmacol. Ther. 2021, 221, 107753. [PubMed]
Tsukamoto, H.; Komohara, Y.; Oshiumi, H. The Role of Macrophages in Anti-Tumor Immune Responses: Pathological Significance
and Potential as Therapeutic Targets. Hum. Cell 2021, 34, 1031–1039.
Shigeoka, M.; Urakawa, N.; Nakamura, T.; Nishio, M.; Watajima, T.; Kuroda, D.; Komori, T.; Kakeji, Y.; Semba, S.; Yokozaki,
H. Tumor Associated Macrophage Expressing CD204 Is Associated with Tumor Aggressiveness of Esophageal Squamous Cell
Carcinoma. Cancer Sci. 2013, 104, 1112–1119. [CrossRef]
Feng, A.; He, L.; Jiang, J.; Chu, Y.; Zhang, Z.; Fang, K.; Wang, Z.; Li, Z.; Sun, M.; Zhao, Z.; et al. Homeobox A7 Promotes
Esophageal Squamous Cell Carcinoma Progression through C-C Motif Chemokine Ligand 2-Mediated Tumor-Associated
Macrophage Recruitment. Cancer Sci. 2023, 114, 3270–3286. [CrossRef] [PubMed]
Chen, J.; Zhao, D.; Zhang, L.; Zhang, J.; Xiao, Y.; Wu, Q.; Wang, Y.; Zhan, Q. Tumor-Associated Macrophage (TAM)-Derived
CCL22 Induces FAK Addiction in Esophageal Squamous Cell Carcinoma (ESCC). Cell. Mol. Immunol. 2022, 19, 1054–1066.
[CrossRef]
Fujikawa, M.; Koma, Y.; Hosono, M.; Urakawa, N.; Tanigawa, K.; Shimizu, M.; Kodama, T.; Sakamoto, H.; Nishio, M.; Shigeoka,
M.; et al. Chemokine (C-C Motif) Ligand 1 Derived from Tumor-Associated Macrophages Contributes to Esophageal Squamous
Cell Carcinoma Progression via CCR8-Mediated Akt/Proline-Rich Akt Substrate of 40 KDa/Mammalian Target of Rapamycin
Pathway. Am. J. Pathol. 2021, 191, 686–703. [CrossRef]
Tanigawa, K.; Tsukamoto, S.; Koma, Y.; Kitamura, Y.; Urakami, S.; Shimizu, M.; Fujikawa, M.; Kodama, T.; Nishio, M.; Shigeoka,
M.; et al. S100A8/A9 Induced by Interaction with Macrophages in Esophageal Squamous Cell Carcinoma Promotes the Migration
and Invasion of Cancer Cells via Akt and P38 MAPK Pathways. Am. J. Pathol. 2022, 192, 536–552. [CrossRef]
Cells 2023, 12, 2603
21.
22.
23.
24.
25.
26.
27.
28.
29.
30.
31.
32.
33.
34.
35.
36.
37.
38.
39.
40.
41.
42.
43.
44.
45.
17 of 18
Kitamura, Y.; Koma, Y.I.; Tanigawa, K.; Tsukamoto, S.; Azumi, Y.; Miyako, S.; Urakami, S.; Kodama, T.; Nishio, M.; Shigeoka, M.;
et al. Roles of IL-7R Induced by Interactions between Cancer Cells and Macrophages in the Progression of Esophageal Squamous
Cell Carcinoma. Cancers 2023, 15, 394. [CrossRef]
Tsukamoto, S.; Koma, Y.I.; Kitamura, Y.; Tanigawa, K.; Azumi, Y.; Miyako, S.; Urakami, S.; Hosono, M.; Kodama, T.; Nishio, M.;
et al. Matrix Metalloproteinase 9 Induced in Esophageal Squamous Cell Carcinoma Cells via Close Contact with Tumor-Associated
Macrophages Contributes to Cancer Progression and Poor Prognosis. Cancers 2023, 15, 2987. [CrossRef]
Holicek, P.; Guilbaud, E.; Klapp, V.; Truxova, I.; Spisek, R.; Galluzzi, L.; Fucikova, J. Type I Interferon and Cancer. Immunol. Rev. 2023.
[CrossRef]
Saleiro, D.; Platanias, L.C. Interferon Signaling in Cancer. Non-Canonical Pathways and Control of Intra-cellular Immune
Checkpoints. Semin. Immunol. 2019, 43, 101299. [PubMed]
Ludlow, L.E.A.; Johnstone, R.W.; Clarke, C.J.P. The HIN-200 Family: More than Interferon-Inducible Genes? Exp. Cell Res. 2005,
308, 1–17. [PubMed]
Wang, Z.; Sheng, B.; Wei, Z.; Li, Y.; Liu, Z. Identification of a Metastasis-Related Protein IFI16 in Esophageal Cancer Using a
Proteomic Approach. J. Cancer 2022, 13, 1630–1639. [CrossRef] [PubMed]
Han, C.; Godfrey, V.; Liu, Z.; Han, Y.; Liu, L.; Peng, H.; Weichselbaum, R.R.; Zaki, H.; Fu, Y.-X. The AIM2 and NLRP3
Inflammasomes Trigger IL-1-Mediated Antitumor Effects during Radiation. Sci. Immunol. 2021, 6, eabc6998.
Ge, D.; Chen, H.; Zheng, S.; Zhang, B.; Ge, Y.; Yang, L.; Cao, X. Hsa-MiR-889-3p Promotes the Proliferation of Osteosarcoma
through Inhibiting Myeloid Cell Nuclear Differentiation Antigen Expression. Biomed. Pharmacother. 2019, 114, 108819. [CrossRef]
Wang, S.; Li, F.; Fan, H. Interferon-Inducible Protein, IFIX, Has Tumor-Suppressive Effects in Oral Squamous Cell Carcinoma. Sci.
Rep. 2021, 11, 19593. [CrossRef]
Japan Esophageal Society. Japanese Classification of Esophageal Cancer, Tenth Edition: Part I. Esophagus 2009, 6, 1–25. [CrossRef]
Japan Esophageal Society. Japanese Classification of Esophageal Cancer, Tenth Edition: Parts II and III. Esophagus 2009, 6, 71–94.
[CrossRef]
Sobin, L.H.; Gospodarowicz, M.K.; Wittekind, C. TNM Classification of Malignant Tumours, 7th ed.; Wiley-Blackwell: Hoboken, NJ,
USA, 2011.
Lin, W.; Zhao, Z.; Ni, Z.; Zhao, Y.; Du, W.; Chen, S. IFI16 Restoration in Hepatocellular Carcinoma Induces Tumour Inhibition via
Activation of P53 Signals and Inflammasome. Cell Prolif. 2017, 50, e12392. [CrossRef] [PubMed]
Chen, J.X.; Cheng, C.S.; Gao, H.F.; Chen, Z.J.; Lv, L.L.; Xu, J.Y.; Shen, X.H.; Xie, J.; Zheng, L. Overexpression of Interferon-Inducible
Protein 16 Promotes Progression of Human Pancreatic Adenocarcinoma Through Interleukin-1β-Induced Tumor-Associated
Macrophage Infiltration in the Tumor Microenvironment. Front. Cell Dev. Biol. 2021, 9, 640786. [CrossRef]
Unterholzner, L.; Keating, S.E.; Baran, M.; Horan, K.A.; Jensen, S.B.; Sharma, S.; Sirois, C.M.; Jin, T.; Latz, E.; Xiao, T.S.; et al. IFI16
Is an Innate Immune Sensor for Intracellular DNA. Nat. Immunol. 2010, 11, 997–1004. [CrossRef] [PubMed]
Li, D.; Xie, L.; Qiao, Z.; Zhu, J.; Yao, H.; Qin, Y.; Yan, Y.; Chen, Z.; Ma, F. IFI16 Isoforms with Cytoplasmic and Nuclear Locations
Play Differential Roles in Recognizing Invaded DNA Viruses. J. Immunol. 2021, 207, 2699–2709. [CrossRef]
Gariano, G.R.; Dell’Oste, V.; Bronzini, M.; Gatti, D.; Luganini, A.; de Andrea, M.; Gribaudo, G.; Gariglio, M.; Landolfo, S. The
Intracellular DNA Sensor IFI16 Gene Acts as Restriction Factor for Human Cytomegalovirus Replication. PLoS Pathog. 2012,
8, e1002498. [CrossRef]
Kerur, N.; Veettil, M.V.; Sharma-Walia, N.; Bottero, V.; Sadagopan, S.; Otageri, P.; Chandran, B. IFI16 Acts as a Nuclear Pathogen
Sensor to Induce the Inflammasome in Response to Kaposi Sarcoma-Associated Herpesvirus Infection. Cell Host Microbe 2011, 9,
363–375. [CrossRef] [PubMed]
Caneparo, V.; Cena, T.; De Andrea, M.; Dell’Oste, V.; Stratta, P.; Quaglia, M.; Tincani, A.; Andreoli, L.; Ceffa, S.; Taraborelli, M.;
et al. Anti-IFI16 Antibodies and Their Relation to Disease Characteristics in Systemic Lupus Erythematosus. Lupus 2013, 22,
607–613. [CrossRef]
Caneparo, V.; Pastorelli, L.; Pisani, L.F.; Bruni, B.; Prodam, F.; Boldorini, R.; Roggenbuck, D.; Vecchi, M.; Landolfo, S.; Gariglio, M.;
et al. Distinct Anti-IFI16 and Anti-GP2 Antibodies in Inflammatory Bowel Disease and Their Variation with Infliximab Therapy.
Inflamm. Bowel Dis. 2016, 22, 2977–2987. [CrossRef]
Alunno, A.; Caneparo, V.; Bistoni, O.; Caterbi, S.; Terenzi, R.; Gariglio, M.; Bartoloni, E.; Manzo, A.; Landolfo, S.; Gerli, R.
Circulating Interferon-Inducible Protein IFI16 Correlates with Clinical and Serological Features in Rheumatoid Arthritis. Arthritis
Care Res. 2016, 68, 440–445. [CrossRef]
Choubey, D.; Panchanathan, R. IFI16, an Amplifier of DNA-Damage Response: Role in Cellular Senescence and Aging-Associated
Inflammatory Diseases. Ageing Res. Rev. 2016, 28, 27–36. [CrossRef] [PubMed]
Jønsson, K.L.; Laustsen, A.; Krapp, C.; Skipper, K.A.; Thavachelvam, K.; Hotter, D.; Egedal, J.H.; Kjolby, M.; Mohammadi, P.;
Prabakaran, T.; et al. IFI16 Is Required for DNA Sensing in Human Macrophages by Promoting Production and Function of
CGAMP. Nat. Commun. 2017, 8, 14391. [CrossRef]
Piccaluga, P.P.; Agostinelli, C.; Fuligni, F.; Righi, S.; Tripodo, C.; Re, M.C.; Clò, A.; Miserocchi, A.; Morini, S.; Gariglio, M.; et al.
IFI16 Expression Is Related to Selected Transcription Factors during B-Cell Differentiation. J. Immunol. Res. 2015, 2015, 747645.
[CrossRef] [PubMed]
Wei, W.; Clarke, C.J.P.; Somers, G.R.; Cresswell, K.S.; Loveland, K.A.; Trapani, J.A.; Johnstone, R.W. Expression of IFI 16 in
Epithelial Cells and Lymphoid Tissues. Histochem. Cell Biol. 2003, 119, 45–54. [CrossRef]
Cells 2023, 12, 2603
46.
47.
48.
49.
50.
51.
52.
53.
54.
55.
56.
57.
58.
59.
60.
61.
62.
63.
64.
65.
66.
18 of 18
Liao, J.C.C.; Lam, R.; Brazda, V.; Duan, S.; Ravichandran, M.; Ma, J.; Xiao, T.; Tempel, W.; Zuo, X.; Wang, Y.X.; et al. InterferonInducible Protein 16: Insight into the Interaction with Tumor Suppressor P53. Structure 2011, 19, 418–429. [CrossRef]
Ka, N.L.; Lim, G.Y.; Hwang, S.; Kim, S.S.; Lee, M.O. IFI16 Inhibits DNA Repair That Potentiates Type-I Interferon-Induced
Antitumor Effects in Triple Negative Breast Cancer. Cell Rep. 2021, 37, 110138. [CrossRef] [PubMed]
He, L.; Xiao, X.; Yang, X.; Zhang, Z.; Wu, L.; Liu, Z. STING Signaling in Tumorigenesis and Cancer Therapy: A Friend or Foe?
Cancer Lett. 2017, 402, 203–212. [CrossRef]
Xu, S.; Li, X.; Liu, Y.; Xia, Y.; Chang, R.; Zhang, C. Inflammasome Inhibitors: Promising Therapeutic Approaches against Cancer.
J. Hematol. Oncol. 2019, 12, 64. [CrossRef]
Dunn, G.P.; Sheehan, K.C.F.; Old, L.J.; Schreiber, R.D. IFN Unresponsiveness in LNCaP Cells Due to the Lack of JAK1 Gene
Expression. Cancer Res. 2005, 65, 3447–3453. [CrossRef]
Zhang, F.; Yuan, Y.; Ma, F. Function and Regulation of Nuclear DNA Sensors During Viral Infection and Tumorigenesis. Front.
Immunol. 2021, 11, 624556. [CrossRef]
Alimirah, F.; Chen, J.; Davis, F.J.; Choubey, D. IFI16 in Human Prostate Cancer. Mol. Cancer Res. 2007, 5, 251–259. [CrossRef]
[PubMed]
Kim, E.J.; Park, J.I.; Nelkin, B.D. IFI16 Is an Essential Mediator of Growth Inhibition, but Not Differentiation, Induced by the
Leukemia Inhibitory Factor/JAK/STAT Pathway in Medullary Thyroid Carcinoma Cells. J. Biol. Chem. 2005, 280, 4913–4920.
[CrossRef]
Cai, H.; Yan, L.; Liu, N.; Xu, M.; Cai, H. IFI16 Promotes Cervical Cancer Progression by Upregulating PD-L1 in Immunomicroenvironment through STING-TBK1-NF-KB Pathway. Biomed. Pharmacother. 2020, 123, 109790. [CrossRef] [PubMed]
Lim, G.Y.; Cho, S.W.; Ka, N.L.; Lee, K.H.; Im, S.A.; Kim, S.S.; Hwang, S.; Lee, M.O. IFI16/Ifi202 Released from Breast Cancer
Induces Secretion of Inflammatory Cytokines from Macrophages and Promotes Tumor Growth. J. Cell. Physiol. 2023, 238,
1507–1519. [CrossRef] [PubMed]
Yu, B.; Zheng, X.; Sun, Z.; Cao, P.; Zhang, J.; Wang, W. IFI16 Can Be Used as a Biomarker for Diagnosis of Renal Cell Carcinoma
and Prediction of Patient Survival. Front. Genet. 2021, 12, 599952. [CrossRef] [PubMed]
Smatlik, N.; Drexler, S.K.; Burian, M.; Röcken, M.; Yazdi, A.S. ASC Speck Formation after Inflammasome Activation in Primary
Human Keratinocytes. Oxid. Med. Cell. Longev. 2021, 2021, 1–13. [CrossRef] [PubMed]
Garlanda, C.; Dinarello, C.A.; Mantovani, A. The Interleukin-1 Family: Back to the Future. Immunity 2013, 39, 1003–1018.
[CrossRef]
Weber, A.; Wasiliew, P.; Kracht, M. Interleukin-1 (IL-1) pathway. Sci. Signal. 2010, 3, cm1. [CrossRef]
Kawaguchi, Y.; Hara, M.; Wright, T.M. Endogenous IL-1α from Systemic Sclerosis Fibroblasts Induces IL-6 and PDGF-A. J. Clin.
Investig. 1999, 103, 1253–1260. [CrossRef]
Douvdevani, A.; Huleihel, M.; Zöller, M.; Segal, S.; Apte, R.N. Reduced Tumorigenicity of Fibrosarcomas Which Constitutively
Generate Il-1α Either Spontaneously or Following Il-1α Gene Transfer. Int. J. Cancer 1992, 51, 822–830. [CrossRef]
Dagenais, M.; Dupaul-Chicoine, J.; Douglas, T.; Champagne, C.; Morizot, A.; Saleh, M. The Interleukin (IL)-1R1 Pathway Is a
Critical Negative Regulator of PyMT-Mediated Mammary Tumorigenesis and Pulmonary Metastasis. Oncoimmunology 2017,
6, 1287247. [CrossRef]
Lin, D.; Mei, Y.; Lei, L.; Binte Hanafi, Z.; Jin, Z.; Liu, Y.; Song, Y.; Zhang, Y.; Hu, B.; Liu, C.; et al. Immune Suppressive Function of
IL-1α Release in the Tumor Microenvironment Regulated by Calpain 1. Oncoimmunology 2022, 11, 2088467. [CrossRef] [PubMed]
Chen, S.; Shen, Z.; Liu, Z.; Gao, L.; Han, Z.; Yu, S.; Kang, M. IL-1RA Suppresses Esophageal Cancer Cell Growth by Blocking
IL-1α. J. Clin. Lab. Anal. 2019, 33, e22903. [CrossRef] [PubMed]
Watari, K.; Shibata, T.; Kawahara, A.; Sata, K.I.; Nabeshima, H.; Shinoda, A.; Abe, H.; Azuma, K.; Murakami, Y.; Izumi, H.; et al.
Tumor-Derived Interleukin-1 Promotes Lymphangiogenesis and Lymph Node Metastasis through M2-Type Macrophages. PLoS
ONE 2014, 9, e99568. [CrossRef] [PubMed]
Murakami, Y.; Watari, K.; Shibata, T.; Uba, M.; Ureshino, H.; Kawahara, A.; Abe, H.; Izumi, H.; Mukaida, N.; Kuwano, M.; et al.
N-Myc Downstream-Regulated Gene 1 Promotes Tumor Inflammatory Angiogenesis through JNK Activation and Autocrine
Loop of Interleukin-1α by Human Gastric Cancer Cells. J. Biol. Chem. 2013, 288, 25025–25037. [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual
author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to
people or property resulting from any ideas, methods, instructions or products referred to in the content.
...
論文の公開元へ
